Company research / TCRX
TScan Therapeutics, Inc. (TCRX)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2025-12-31, TScan Therapeutics, Inc. reported revenue of $10.32M. Revenue grew 266.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $7.11M.
Key ratios (year ended 2025-12-31)
n/m
Operating margin
n/m
Net margin
-105.4%
Return on year-end equity
266.7%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.